Bharat Biotech increased production of Covaxin to 700 million doses per year

Hyderabad, 20 April 2021 Tuesday

COVID-19 vaccine Covaxin manufacturer Bharat Biotech said in a statement on Tuesday that the company has increased its production capacity of COVID-19 vaccine Covaxin to 700 million doses per year, with the city-based vaccine manufacturer gradually increasing its production capacity in Hyderabad and Bangalore. .

According to company sources, when the COVID-19 vaccine Covaxin was launched, the company had a capacity of 200 million doses, increasing the production of the vaccine is a long and tedious process, and requires capital investment and many years.

The main reason why India Biotech has been able to produce the Covaxin vaccine in a short period of time is the specially designed BSL-3 facilities, the first of its kind in India to produce a high-purity virus vaccine.

Bharat Biotech has started looking for partners for corona vaccine production with foreign manufacturers who have commercial capabilities to produce viral vaccines in other countries, India Biotech has partnered with Indian Immunologicals (IIL) for further production of Covaxin for further production of vaccines. .